Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy
Background The OXEL study (NCT03487666) was a phase II trial of patients with triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy, randomized to receive immunotherapy (anti-programmed cell death protein 1, nivolumab), chemotherapy (capecitabine), or chemoimm...
Đã lưu trong:
| Những tác giả chính: | , , , , , , |
|---|---|
| Định dạng: | Artigo |
| Ngôn ngữ: | Inglês |
| Được phát hành: |
BMJ Publishing Group
2025-04-01
|
| Loạt: | Journal for ImmunoTherapy of Cancer |
| Truy cập trực tuyến: | https://jitc.bmj.com/content/13/4/e011379.full |
| Các nhãn: |
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|